Skip to main content

Advertisement

Table 1 Clinical characteristics at cross-sectional visit of patients in MTX and biologic era cohorts

From: Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era

  MTX era (n = 239) Biologic era (n = 269) P
Female 189 (79.1) 219 (81.4) 0.51
Median (IQR) age at disease onset, years 3.1 (1.8–5.8) 2.5 (1.6–4.7) 0.016
Median (IQR) disease duration at study visit, years 7.7 (6.1–10.2) 6.9 (5.4–9.7) 0.0005
Median (IQR) disease duration at first observation, years 0.7 (0.2–2.0) 0.6 (0.2–1.8) 0.52
ILAR category
 Systemic arthritis 23 (9.6) 17 (6.3) 0.0025
 RF-negative polyarthritis 49 (20.5) 51 (19.0)
 RF-positive polyarthritis 5 (2.1) 0.0 (0.0)
 Persistent oligoarthritis 73 (30.5) 119 (44.2)
 Extended oligoarthritis 55 (23.0) 63 (23.4)
 Psoriatic arthritis 15 (6.3) 7 (2.6)
 Undifferentiated arthritis 19 (7.9) 12 (4.5)
 Patients with positive ANA 184 (77.0) 221 (82.2) 0.05
Past treatment
 Methotrexate 153 (64.0) 209 (77.7) 0.0007
 Cyclosporin A 58 (24.3) 19 (7.0) < 0.0001
 Sulfasalazine 17 (7.1) 7 (2.6) 0.017
 Biologic DMARDs 26 (10.9) 99 (36.8) < 0.0001
 Etanercept 23 (9.6) 84 (31.2) < 0.0001
 Infliximab 5 (2.1) 4 (1.5) 0.74
 Adalimumab 27 (10.0)
 Anakinra 7 (2.6)
 Abatacept 3 (1.1)
 Tocilizumab 4 (1.5)
 Systemic glucocorticoids 92 (38.5) 85 (31.6) 0.10
 Intraarticular glucocorticoids 187 (78.2) 250 (93.0) < 0.0001
Present treatment
 Methotrexate 90/200 (45.0) 95/266 (35.7) 0.043
 Cyclosporin A 18/200 (9.0) 3/266 (1.1) < 0.0001
 Biologic DMARDs 16/200 (8.0) 89/266 (33.5) < 0.0001
 Systemic glucocorticoids 8/200 (4.0) 8/266 (3.0) 0.56
 No therapy 52/200 (26.0) 90/266 (33.8) 0.069
  1. Data are number positive/number with information available (percentage) unless otherwise indicated; reference [11]
  2. MTX methotrexate, IQR interquartile range, RF rheumatoid factor, ANA antinuclear antibodies, DMARDs disease antirheumatic drugs